lorigerlimab
lorigerlimab: 7 clinical trials tracked.
lorigerlimab evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about lorigerlimab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trial Registry Records (7)
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Primary endpoint: Safety and adverse events (AEs)
Phase II Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
Primary endpoint: Safety and Adverse Events (AEs)
A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors
Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator
A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Median radiographic progression free survival (rPFS) determined by investigator review.
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Primary endpoint: To establish overall survival (OS)
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Primary endpoint: Number of participants with adverse events (AEs)
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Primary endpoint: Incidence of treatment-emergent adverse events